Morgan Stanley started coverage on shares of Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) in a research note issued to investors on Thursday, The Fly reports. The firm set an “overweight” rating and a $17.00 price target on the biotechnology company’s stock. Morgan Stanley’s target price indicates a potential upside of 96.99% from the company’s current price.
Other equities research analysts have also issued research reports about the stock. SVB Leerink started coverage on shares of Alpine Immune Sciences in a report on Monday, November 21st. They issued an “outperform” rating and a $15.00 price target on the stock. Oppenheimer lowered their target price on shares of Alpine Immune Sciences from $17.00 to $14.00 and set an “outperform” rating on the stock in a report on Monday, October 24th. Finally, HC Wainwright lowered their target price on shares of Alpine Immune Sciences from $21.00 to $8.00 in a report on Monday, October 24th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Alpine Immune Sciences currently has an average rating of “Buy” and an average target price of $15.80.
Alpine Immune Sciences Price Performance
Shares of Alpine Immune Sciences stock opened at $8.63 on Thursday. The firm has a market capitalization of $262.36 million, a PE ratio of -4.82 and a beta of 1.28. The company’s fifty day moving average price is $6.95 and its two-hundred day moving average price is $7.38. Alpine Immune Sciences has a 52-week low of $4.82 and a 52-week high of $10.30.
Institutional Investors Weigh In On Alpine Immune Sciences
Large investors have recently made changes to their positions in the company. Monashee Investment Management LLC bought a new stake in shares of Alpine Immune Sciences in the 3rd quarter worth about $720,000. Caas Capital Management LP bought a new stake in Alpine Immune Sciences during the 3rd quarter worth about $327,000. Commodore Capital LP bought a new stake in Alpine Immune Sciences during the 3rd quarter worth about $9,540,000. Lynx1 Capital Management LP grew its holdings in Alpine Immune Sciences by 58.6% during the 3rd quarter. Lynx1 Capital Management LP now owns 3,056,420 shares of the biotechnology company’s stock worth $22,006,000 after acquiring an additional 1,129,551 shares during the last quarter. Finally, RA Capital Management L.P. bought a new stake in Alpine Immune Sciences during the 3rd quarter worth about $31,368,000.
About Alpine Immune Sciences
Alpine Immune Sciences, Inc is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies.
- Get a free copy of the StockNews.com research report on Alpine Immune Sciences (ALPN)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.